Is Genetic Technologies Stock a Good Investment?
Genetic Technologies Investment Advice | GENE |
- Examine Genetic Technologies' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Genetic Technologies' leadership team and their track record. Good management can help Genetic Technologies navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Life Sciences Tools & Services space and any emerging trends that could impact Genetic Technologies' business and its evolving consumer preferences.
- Compare Genetic Technologies' performance and market position to its competitors. Analyze how Genetic Technologies is positioned in terms of product offerings, innovation, and market share.
- Check if Genetic Technologies pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Genetic Technologies' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Genetic Technologies stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Genetic Technologies is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Genetic Technologies Stock
Researching Genetic Technologies' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The book value of the company was currently reported as 0.01. The company recorded a loss per share of 0.02. Genetic Technologies last dividend was issued on the 15th of August 2019. The entity had 1:5 split on the 14th of December 2023.
To determine if Genetic Technologies is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Genetic Technologies' research are outlined below:
| Genetic Technologies generated a negative expected return over the last 90 days | |
| Genetic Technologies has some characteristics of a very speculative penny stock | |
| Genetic Technologies has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 7.66 M. Net Loss for the year was (12.02 M) with profit before overhead, payroll, taxes, and interest of 6.01 M. | |
| Genetic Technologies currently holds about 11.74 M in cash with (9.68 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76. | |
| Latest headline from investing.com: Genetic Technologies appoints voluntary administrators |
Genetic Technologies uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Genetic Technologies. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Genetic Technologies' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 29th of August 2023 Upcoming Quarterly Report | View | |
| 30th of June 2023 Next Fiscal Quarter End | View |
Know Genetic Technologies' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Genetic Technologies is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Genetic Technologies backward and forwards among themselves. Genetic Technologies' institutional investor refers to the entity that pools money to purchase Genetic Technologies' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Susquehanna International Group, Llp | 2024-06-30 | 77.3 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 36 K | Bnp Paribas Arbitrage, Sa | 2024-06-30 | 12.6 K | Rhumbline Advisers | 2024-06-30 | 3.7 K | Citadel Advisors Llc | 2024-09-30 | 682 | Federation Des Caisses Desjardins Du Quebec | 2024-06-30 | 400 | Simplex Trading, Llc | 2024-06-30 | 255 | Ashton Thomas Securities, Llc | 2024-09-30 | 5.0 | Armistice Capital, Llc | 2024-09-30 | 0.0 | Ubs Group Ag | 2024-06-30 | 0.0 |
Genetic Technologies' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.71 M.Market Cap |
|
Genetic Technologies' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.97) | (2.82) | |
| Return On Capital Employed | (3.28) | (3.12) | |
| Return On Assets | (1.94) | (1.85) | |
| Return On Equity | (6.57) | (6.24) |
Determining Genetic Technologies' profitability involves analyzing its financial statements and using various financial metrics to determine if Genetic Technologies is a good buy. For example, gross profit margin measures Genetic Technologies' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Genetic Technologies' profitability and make more informed investment decisions.
Please note, the presentation of Genetic Technologies' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Genetic Technologies' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Genetic Technologies' management manipulating its earnings.
Evaluate Genetic Technologies' management efficiency
Genetic Technologies has return on total asset (ROA) of (0.6293) % which means that it has lost $0.6293 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8498) %, meaning that it created substantial loss on money invested by shareholders. Genetic Technologies' management efficiency ratios could be used to measure how well Genetic Technologies manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -2.82. The current year's Return On Capital Employed is expected to grow to -3.12. At present, Genetic Technologies' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 10.6 M, whereas Non Current Assets Total are forecasted to decline to about 2.4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.01 | 0.01 | |
| Enterprise Value Over EBITDA | (0.92) | (0.88) | |
| Price Book Value Ratio | 5.85 | 5.56 | |
| Enterprise Value Multiple | (0.92) | (0.88) | |
| Price Fair Value | 5.85 | 5.56 | |
| Enterprise Value | 10.6 M | 10 M |
Leadership effectiveness at Genetic Technologies is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Beta 0.48 |
Basic technical analysis of Genetic Stock
As of the 30th of November, Genetic Technologies retains the Standard Deviation of 1.69, risk adjusted performance of (0.12), and Market Risk Adjusted Performance of 2.08. Genetic Technologies technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Genetic Technologies variance, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to decide if Genetic Technologies is priced fairly, providing market reflects its last-minute price of 0.77 per share. As Genetic Technologies is a penny stock we also advise to confirm its jensen alpha numbers.Genetic Technologies' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Genetic Technologies insiders, such as employees or executives, is commonly permitted as long as it does not rely on Genetic Technologies' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Genetic Technologies insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Hennessey Robert J over two weeks ago Disposition of 10000 shares by Hennessey Robert J of Genetic Technologies at 5.5003 subject to Rule 16b-3 | ||
Loucks Vernon R Jr over three weeks ago Disposition of tradable shares by Loucks Vernon R Jr of Genetic Technologies subject to Rule 16b-3 | ||
Hennessey Robert J over a month ago Acquisition by Hennessey Robert J of 14000 shares of Genetic Technologies at 1.625 subject to Rule 16b-3 | ||
Kirby Pamela J over a month ago Insider Trading | ||
Riedel Norbert G over two months ago Acquisition by Riedel Norbert G of 271 shares of Genetic Technologies at 1.98 subject to Rule 16b-3 | ||
Riedel Norbert G over three months ago Acquisition by Riedel Norbert G of 547 shares of Genetic Technologies at 1.57 subject to Rule 16b-3 | ||
Hennessey Robert J over six months ago Acquisition by Hennessey Robert J of 223 shares of Genetic Technologies at 1.93 subject to Rule 16b-3 |
Genetic Technologies' Outstanding Corporate Bonds
Genetic Technologies issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Genetic Technologies uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Genetic bonds can be classified according to their maturity, which is the date when Genetic Technologies has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Genesis Energy 775 Corp BondUS37185LAL62 | View | |
| GEL 8875 15 APR 30 Corp BondUS37185LAN29 | View | |
| US37185LAM46 Corp BondUS37185LAM46 | View |
Understand Genetic Technologies' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Genetic Technologies' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.12) | |||
| Market Risk Adjusted Performance | 2.08 | |||
| Mean Deviation | 1.07 | |||
| Coefficient Of Variation | (620.51) | |||
| Standard Deviation | 1.69 | |||
| Variance | 2.84 | |||
| Information Ratio | (0.24) | |||
| Jensen Alpha | (0.26) | |||
| Total Risk Alpha | (0.56) | |||
| Treynor Ratio | 2.07 | |||
| Maximum Drawdown | 8.88 | |||
| Value At Risk | (3.53) | |||
| Potential Upside | 2.63 | |||
| Skewness | (0.38) | |||
| Kurtosis | 1.8 |
| Risk Adjusted Performance | (0.12) | |||
| Market Risk Adjusted Performance | 2.08 | |||
| Mean Deviation | 1.07 | |||
| Coefficient Of Variation | (620.51) | |||
| Standard Deviation | 1.69 | |||
| Variance | 2.84 | |||
| Information Ratio | (0.24) | |||
| Jensen Alpha | (0.26) | |||
| Total Risk Alpha | (0.56) | |||
| Treynor Ratio | 2.07 | |||
| Maximum Drawdown | 8.88 | |||
| Value At Risk | (3.53) | |||
| Potential Upside | 2.63 | |||
| Skewness | (0.38) | |||
| Kurtosis | 1.8 |
Consider Genetic Technologies' intraday indicators
Genetic Technologies intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Genetic Technologies stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Genetic Technologies time-series forecasting models is one of many Genetic Technologies' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Genetic Technologies' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Genetic Stock media impact
Far too much social signal, news, headlines, and media speculation about Genetic Technologies that are available to investors today. That information is available publicly through Genetic media outlets and privately through word of mouth or via Genetic internal channels. However, regardless of the origin, that massive amount of Genetic data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Genetic Technologies news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Genetic Technologies relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Genetic Technologies' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Genetic Technologies alpha.
Genetic Technologies Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Genetic Technologies can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Genetic Technologies Corporate Management
| Kevin Camilleri | Chief EasyDNA | Profile | |
| CPA BCom | Chief Secretary | Profile | |
| AGIA BCom | CFO Sec | Profile | |
| Bus FCI | Consultant | Profile | |
| Simon Morriss | Chief Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genetic Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Genetic Stock refer to our How to Trade Genetic Stock guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genetic Technologies. If investors know Genetic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genetic Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.02) | Revenue Per Share 2.19 | Quarterly Revenue Growth (0.11) | Return On Assets (0.63) | Return On Equity (1.85) |
The market value of Genetic Technologies is measured differently than its book value, which is the value of Genetic that is recorded on the company's balance sheet. Investors also form their own opinion of Genetic Technologies' value that differs from its market value or its book value, called intrinsic value, which is Genetic Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genetic Technologies' market value can be influenced by many factors that don't directly affect Genetic Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Genetic Technologies' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Genetic Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genetic Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.